Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.

@article{Krishna2007EffectOA,
  title={Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.},
  author={R. P. Brijesh Krishna and Arthur James Bergman and Patrick Larson and J{\'e}r{\^o}me C{\^o}t{\'e} and Kenneth C. Lasseter and Stacey C Dilzer and Amy Y. X. Wang and Wei Zeng and Li Chen and John Arthur Wagner and Gary A. Herman},
  journal={Journal of clinical pharmacology},
  year={2007},
  volume={47 2},
  pages={
          165-74
        }
}
Sitagliptin (MK-0431) is an orally active, potent, and selective dipeptidyl peptidase-4 inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin has been shown to be a substrate for P-glycoprotein in preclinical studies. Cyclosporine was used as a probe P-glycoprotein inhibitor at a high dose to evaluate the potential effect of potent P-glycoprotein inhibition on single-dose sitagliptin pharmacokinetics in healthy male subjects. Eight healthy young men received a… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Pharmacokinetic Interaction Study of Ticagrelor and Cyclosporine in Healthy Volunteers

  • Clinical drug investigation
  • 2014
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2015

Similar Papers

Loading similar papers…